Owen N Witte

List of Publications by Year in Descending Order

67 papers	6,068 citations	35 h-index	68 g-index
68 ext. papers	6,998 ext. citations	14.6 avg, IF	5.2 L-index

#	Paper	IF	Citations
67	RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets. *Trends in Pharmacological Sciences*, **2021**, 42, 268-282	13.2	5
66	Droplet-based mRNA sequencing of fixed and permeabilized cells by CLInt-seq allows for antigen-specific TCR cloning. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	2
65	HLA-A02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses.. *Cell Reports*, **2021**, 37, 110167	10.6	1
64	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12315-12323	11.5	28
63	Targeting RET Kinase in Neuroendocrine Prostate Cancer. *Molecular Cancer Research*, **2020**, 18, 1176-1186	5.6	11
62	Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 5269-5279	11.5	18
61	F-FAC PET Visualizes Brain-Infiltrating Leukocytes in a Mouse Model of Multiple Sclerosis. *Journal of Nuclear Medicine*, **2020**, 61, 757-763	8.9	7
60	A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 563-572	11.5	13
59	Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood. *Cell Reports*, **2019**, 28, 2728-2738.e7	10.6	42
58	Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. *Cell Stem Cell*, **2019**, 25, 542-557.e9	18	23
57	T cell antigen discovery via trogocytosis. *Nature Methods*, **2019**, 16, 183-190	21.6	53
56	Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. *Cancer Cell*, **2019**, 36, 17-34.e7	24.3	47
55	Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. *Science Translational Medicine*, **2019**, 11,	17.5	24
54	IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. *Clinical Cancer Research*, **2019**, 25, 1000-1011	12.9	7
53	Noninvasive Imaging of Drug-Induced Liver Injury with F-DFA PET. *Journal of Nuclear Medicine*, **2018**, 59, 1308-1315	8.9	7
52	Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E4473-E4482	11.5	56
51	F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis. *Journal of Nuclear Medicine*, **2018**, 59, 1616-1623	8.9	9

50	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. *Journal of Clinical Oncology*, **2018**, 36, 2492-2503	2.2	271
49	Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. *Science*, **2018**, 362, 91-95	33.3	139
48	Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E10702-E10711	11.5	35
47	A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. *Cell Reports*, **2018**, 24, 3353-3366.e5	10.6	49
46	Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1 pre-B ALL. *Journal of Experimental Medicine*, **2017**, 214, 793-814	16.6	21
45	FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. *Modern Pathology*, **2017**, 30, 1262-1272	9.8	46
44	[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 4027-32	11.5	55
43	Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E172-81	11.5	33
42	An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. *Cancer Research*, **2016**, 76, 73-82	10.1	206
41	Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. *Cell Reports*, **2016**, 17, 2596-2606	10.6	67
40	Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 4482-7	11.5	66
39	N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. *Cancer Cell*, **2016**, 29, 536-547	24.3	189
38	Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E6457-E6466	11.5	32
37	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. *Cell*, **2016**, 166, 1041-1054	56.2	132
36	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. *Cancer Cell*, **2015**, 28, 97-113	24.3	116
35	Lift NIH restrictions on chimera research. *Science*, **2015**, 350, 640	33.3	11
34	Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies. *Journal of Nuclear Medicine*, **2015**, 56, 1258-64	8.9	84
33	A basal stem cell signature identifies aggressive prostate cancer phenotypes. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E6544-52	11.5	131

32	Preparation of Urogenital Sinus Mesenchymal Cells for Prostate Tissue Recombination Models. *Cold Spring Harbor Protocols*, **2015**, 2015, 988-90	1.2	3
31	Dissociated Prostate Regeneration under the Renal Capsule. *Cold Spring Harbor Protocols*, **2015**, 2015, 991-4	1.2	3
30	Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 1523-8	11.5	23
29	Tissue Recombination Models for the Study of Epithelial Cancer. *Cold Spring Harbor Protocols*, **2015**, 2015, pdb.top069880	1.2	3
28	HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. *Cancer Research*, **2014**, 74, 5173-83	10.1	26
27	Positron emission tomography probe demonstrates a striking concentration of ribose salvage in the liver. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E2866-74	11.5	15
26	Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance. *PLoS ONE*, **2014**, 9, e104125	3.7	18
25	Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 20111-6	11.5	114
24	Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4762-9	11.5	82
23	A Pre-Clinical Model Of Hematopoietic Stem Cell Based Immunotherapy For Cancer Utilizing The NY-ESO-1 T-Cell Receptor and sr39TK PET Reporter / Suicide Gene. *Blood*, **2013**, 122, 2020-2020	2.2	
22	Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 1643-8	11.5	115
21	Purification and direct transformation of epithelial progenitor cells from primary human prostate. *Nature Protocols*, **2011**, 6, 656-67	18.8	74
20	Identification of a cell of origin for human prostate cancer. *Science*, **2010**, 329, 568-71	33.3	442
19	The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 6942-7	11.5	375
18	Modeling Philadelphia chromosome positive leukemias. *Oncogene*, **2001**, 20, 5644-59	9.2	59
17	Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. *Science*, **2001**, 293, 702-5	33.3	282
16	Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia. *Stem Cells*, **2000**, 18, 399-408	5.8	53
15	Target antigens for prostate cancer immunotherapy. *Cancer and Metastasis Reviews*, **1999**, 18, 437-49	9.6	25

14	A Btk transgene restores the antiviral TI-2 antibody responses of xid mice in a dose-dependent fashion. *European Journal of Immunology*, **1999**, 29, 2981-7	6.1	20
13	Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. *Oncogene*, **1998**, 16, 1383-90	9.2	193
12	Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. *Journal of Orthopaedic Research*, **1998**, 16, 330-9	3.8	256
11	Development of Acute Lymphoblastic Leukemia and Myeloproliferative Disorder in Transgenic Mice Expressing p210bcr/abl: A Novel Transgenic Model for Human Ph1-Positive Leukemias. *Blood*, **1998**, 91, 2067-2075	2.2	10
10	Constitutive membrane association potentiates activation of Bruton tyrosine kinase. *Oncogene*, **1997**, 15, 1375-83	9.2	61
9	Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. *Nature Medicine*, **1997**, 3, 402-8	50.5	319
8	Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence. *FEBS Letters*, **1996**, 379, 244-6	3.8	18
7	Bruton's tyrosine kinase is a key regulator in B-cell development. *Immunological Reviews*, **1994**, 138, 105-19	11.3	98
6	Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. *Science*, **1993**, 261, 358-61	33.3	774
5	Delay of early B-lymphocyte development by gamma 2b immunoglobulin transgene: effect on differentiation-specific molecules. *Autoimmunity*, **1990**, 1, 105-12		5
4	Molecular pathogenesis of Ph-positive leukemias. *Annual Review of Medicine*, **1989**, 40, 113-22	17.4	36
3	Long-term culture systems for analysis of early B lymphocyte development. *International Reviews of Immunology*, **1987**, 2, 285-305	4.6	2
2	Expression of a translocated c-abl gene in hybrids of mouse fibroblasts and chronic myelogenous leukaemia cells. *Nature*, **1986**, 319, 331-3	50.4	22
1	Differential expression of myc family genes during murine development. *Nature*, **1986**, 319, 780-3	50.4	486